Background
Methods
Study period and participating institutions
Bacterial isolates
Antimicrobial susceptibility testing
Definitions
Statistical analysis
Results
Demographic analysis
Pts with AUC (%) | Total patients sample with available clinical information | |
---|---|---|
No of patients (% of total) | 172 (51.5) | 334 (100) |
Gender (% female) | 100 | 88.3 |
Age (mean ± S.D.) (range) (years) | 42.6 ± 17.0 (16–93) | 46.9 ± 18.6 (16–93) |
15–65 | 141 (82.0) | 248 (74.3) |
>65 | 25 (14.0) *
| 70 (20.9) |
Missing | 7 (4.0) | 16 (4.8) |
History of previous UTI in the last 2 weeks | 0a
| 13 (3.9) |
History of admission in the last year | 11 (6.4) *
| 39 (11.7) |
History of urinary catheter placement during admission | 7 (4.1) | 18 (5.4) |
Diabetes mellitus | 0a
| 30 (9.0) |
Nephrolithiasis | 0a
| 27 (8.1) |
Actively having a urinary catheter | 0 a
| 15 (4.5) |
Pregnancy | 0a
| 6 (1.8) |
History of UTI in the last 3 months | 16 (9.3) *
| 51 (15.3) |
History of UTI in the past | 64 (37.2) | 122 (36.5) |
History of receiving an antibiotic in the last 3 months for reason other than UTI | 33 (19.2) | 62 (18.6) |
Antimicrobial susceptibility testing for the total sample population
Antimicrobial agent | Escherichia coli (n = 330) | Klebsiella spp (n = 91) | Proteus mirabilis (n = 142) |
---|---|---|---|
Amoxicillin | 31.5 | N/A b
| 33.1 |
Amoxicillin/clavulanic acid | 6.4 | 1.1 | 4.2 |
Cefalothin | 9.1 | 3.3 | 13.4 |
Cefuroxime sodium | 2.7 | 1.1 | 1.4 |
Cefuroxime axetil | 3.9 | 3.3 | 2.8 |
Co-trimoxazole | 23.6 | 11.0 | 13.4 |
Nalidixic acid | 8.2 | 9.9 | 5.6 |
Ciprofloxacin | 4.8 | 5.5 | 1.4 |
Mecillinam | 3.6 | 1.1 | 22.5 |
Nitrofurantoin | 6.4 | 30.8 | N/A b
|
Fosfomycin c
| 1.2 | 1.1 | 9.9 |
Cefotaxime | 3.0 | 1.1 | 1.4 |
Ceftazidime | 0.6 | 1.1 | 3.5 |
Gentamicin | 2.1 | 1.1 | 4.2 |
Netilimicin | 0.6 | 1.1 | 0.7 |
Amikacin | 0.9 | 1.1 | 0 |
Piperacillin-tazobactam | 0.6 | 1.1 | 0 |
Ticarcillin-clavulanate | 0.9 | 1.1 | 0.7 |
Imipenem | 0.6 | 0 | 0.7 |
Cefditoren | 3.0 | 3.3 | 2.1 |
Antimicrobial susceptibility testing for the study population with available clinical data
Antimicrobial agent | AUC (n = 119) | TotalE. coli cases with available clinical info (n = 214) |
---|---|---|
Amoxicillin | 26.1 | 27.6 |
Amoxicillin/clavulanic acid | 5.0 | 4.7 |
Cefalothin | 6.7 | 7.9 |
Cefuroxime sodiumb
| 0.8 | 1.4 |
Cefuroxime axetilc
| 2.5 | 3.3 |
Co-trimoxazole | 18.5 | 18.7 |
Nalidixic acid | 5.0 | 7.9 |
Ciprofloxacin | 1.7 | 4.2 |
Mecillinam | 2.5 | 2.8 |
Nitrofurantoin | 7.6 | 7.0 |
Fosfomycin d
| 0 | 0.5 |
Cefotaxime | 0.8 | 2.3 |
Ceftazidime | 0 | 0 |
Gentamicin | 0 | 1.4 |
Netilimicin | 0 | 0.5 |
Amikacin | 0 | 0 |
Piperacillin-tazobactam | 0 | 0 |
Ticarcillin-clavulanate | 0.8 | 0.9 |
Imipenem | 0 | 0 |
Cefditoren | 1.7 | 1.9 |
Antimicrobial agent |
Proteus mirabilis
|
Klebsiellaspp. | ||
---|---|---|---|---|
AUCb(n = 31) | Total cases with available clinical information (n = 75) | AUCb(n = 22) | Total cases with available clinical information (n = 45) | |
Amoxicillin | 35.5 | 33.3 | N/A c
| N/A c
|
Amoxicillin/clavulanic acid | 6.5 | 5.3 | 0 | 2.2 |
Cefalothin | 12.9 | 12.0 | 4.5 | 4.4 |
Cefuroxime sodium | 0 | 2.7 | 0 | 0 |
Cefuroxime axetil | 3.2 | 5.3 | 4.5 | 2.2 |
Co-trimoxazole | 16.1 | 16 | 9.1 | 11.1 |
Nalidixic acid | 9.7 | 6.7 | 0* | 8.9 |
Ciprofloxacin | 6.5 | 2.7 | 0 | 4.4 |
Mecillinam | 25.8 | 21.3 | 0 | 0 |
Nitrofurantoin | N/A c
| N/A c
| 40.9 | 33.3 |
Fosfomycin | 0 | 0 | 0 | 2.2 |
Cefotaxime | 3.2 | 3.2 | 0 | 0 |
Ceftazidime | 6.5 | 5.3 | 0 | 0 |
Gentamicin | 0 | 2.7 | 0 | |
Netilimicin | 0 | 0 | 0 | 2.2 |
Amikacin | 0 | 0 | 4.5 | 4.4 |
Piperacillin-tazobactam | 0 | 0 | 0 | 0 |
Ticarcillin-clavulanate | 0 | 0 | 0 | 0 |
Imipenem | 0 | 0 | 0 | 0 |
Cefditoren | 3.2 | 2.7 | 0 | 2.2 |
Risk factors for cefditoren non-susceptibility
Cefditoren susceptible strains | Cefditoren non-susceptible strains | P | |
---|---|---|---|
Ciprofloxacin MIC50/MIC90 (mg/L) | 0.012/0.032 | 0.19/32 | <0.001 |
Nalidixic acid susceptible strains | Nalidixic acid non-susceptible strains | P | |
Cefditoren MIC50/MIC90 (mg/L) | 0.25/0.5 | 0.25/48 | <0.001 |
Ciprofloxacin susceptible strains | Ciprofloxacin non-susceptible strains | P | |
Cefditoren MIC50/MIC90 (mg/L) | 0.25/0.5 | 0.5/64 | <0.001 |
Parameter |
p value | Odds Ratio | 95% Confidence Interval |
---|---|---|---|
Presence of fever | 0.14 | 5.69 | 0.58-55.54 |
History of UTI in the previous 2 weeks | 0.006 | 39.65 | 2.88-546.30 |
History of UTI in the previous 3 months | 0.04 | 22.67 | 1.12-457.48 |
Fluoroquinolone use in the last 3 months | 0.32 | 0.16 | 0.04-5.89 |
Cephalosporin or clavulanate fixed combination in the last 3 months | 0.86 | 0.78 | 0.05-11.48 |
Isolate | MIC Cefdi | CIP | AN | AMC | AM | Cefot CTX | CAZ | Cefur CXM | Cefal CF | FOS | GM | IMP | MEC | NA | NET | FT | TZP | TCC | SXT | Resistance Phenotype | Clinical details available |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
BA 356
E. coli
| 1 | S | S | I | R | S | S | S | S | S | S | S | S | S | S | S | S | S | S | TEM-1 hyperproduction | NA |
BA 425
E. coli
| 1 | S | S | S | R | S | S | S | S | S | S | S | S | S | S | S | S | S | R | TEM-1 + SXTR
| 75ys female AUC, doxycycline in the last 3mos |
BC 165
E. coli
| 1 | S | S | R | R | S | S | S | R | S | S | S | S | S | S | S | S | S | S | TEM-1 hyperproduction | 25ys female UTI, Hx of UTI in the last 2wks |
BC 211
E. coli
| 1 | R | S | I | R | S | S | S | R | S | S | S | S | R | S | S | S | S | R | TEM-1 hyperproduction + SXTR + cross resistance to all fluoroquinolones | 81ys female AB with diabetes mellitus and nephrolithiasis, Hx of UTI in the last 2ks and 3 mos, use of CIP in the last 3mos |
BTH 486
E. coli
| 1 | S | S | I | R | S | S | S | S | S | S | S | S | S | S | S | S | S | R | TEM-1 hyperproduction + SXTR
| NA |
BM 538
E. coli
| 1 | S | S | I | R | S | S | S | R | S | S | S | S | S | S | S | S | S | S | TEM-1 hyperproduction | NA |
PER 41ii
E. coli
| 1 | S | S | S | R | S | S | S | S | S | S | S | S | S | S | S | S | S | S | TEM-1 | 45ys male AB, Hx of UTI in the last year |
BTH 229
Klebsiella
spp
| 2 | S | S | S | R | S | S | S | S | S | S | S | S | S | S | I | S | S | R | SHV-1 natural + FTR + SXTR
| NA |
BP 129
E. coli
| 2 | - | S | R | R | S | S | I | R | R | S | S | S | S | S | R | S | S | S | TEM-1 hyperproduction + FTR + FOSR
| NA |
P 72
Klebsiella
spp
| 2 | R | S | S | R | S | S | S | S | S | S | S | S | R | S | R | S | S | R | SHV-1 + FTR + SXTR + cross resistance to all fluoroquinolones | 80ys female AB with folley catheter, Hx of UTI in the last 2wks and 3mos, use of cefaclor and TZP in the last 3 months |
BK 319
E. coli
| 4 | R | S | I | R | S | S | S | S | S | S | S | S | R | S | S | S | S | R | TEM-1 hyperproduction + SXTR + cross resistance to all fluoroquinolones | 18ys female AUC, Hx of UTI in the last 3mos |
BA 569
E. coli
| 16 | S | S | S | R | R | S | R | R | S | S | S | S | S | S | S | S | S | R | ESBL CTX-type + SXTR
| NA |
BTH 470
E. coli
| 32 | S | S | S | R | R | S | R | R | S | S | S | S | R | S | S | S | S | S | ESBL CTX-type + Resistance quinolones NalR
| 40ys female AUC, Hx of UTI in the last year |
BM 593
E. coli
| 32 | S | S | S | R | R | S | R | R | S | S | S | S | R | S | S | S | S | R | ESBL CTX-type + SXTR + Resistance quinolones NalR
| NA |
BA 524
Klebsiella
spp
| 64 | R | S | S | R | R | R | R | R | S | S | S | R | R | S | S | S | S | S | ESBL + MecilinamR + Cross resistance to all fluoroquinolones | NA |
BM 463
P. mirabilis
| 64 | S | S | R | R | S | S | S | R | S | S | S | S | S | S | R | S | S | S | AmpC plasmidic + natural FTR
| 56ys female, fever-frequency-dysuria-pyuria, use of cefaclor in the last 3 mos |
BM 465
P. mirabilis
| 64 | S | S | R | R | S | S | S | R | S | S | S | S | S | S | R | S | S | S | AmpC plasmidic + natural FTR
| 36ys female AUC, history of UTI in the last 3mos and use of CIP |
BM 466
P. mirabilis
| 64 | S | S | R | R | S | S | S | R | S | S | S | S | S | S | R | S | S | S | AmpC plasmidic + natural FTR
| NA |
BA 315
E. coli
| 128 | S | S | I | R | R | S | R | R | S | S | S | S | R | S | S | S | I | I | ESBL CTX-type + SXTR + Resistance quinolones NalR
| 80ys female AB with folley catheter, Hx of UTI in the last 3mos, use of SXT and TZP in the last 3mos, recent hospital admission |
GEM 167
E. coli
| 128 | S | S | I | R | R | S | R | R | S | S | S | S | S | S | S | S | S | R | ESBL CTX-type + SXTR
| NA |
GEM 250
E. coli
| 128 | R | S | S | R | R | S | R | R | S | S | S | S | R | S | S | S | S | R | ESBL CTX-type + SXTR + Cross resistance to all fluoroquinolones | 68ys female, fever-pyuria, diabetes mellitus and nephrolithiasis, Hx of UTI in the last 2wks and use of CIP, Hx of recent hospital admission |
GEM 315
E. coli
| 128 | S | R | S | R | R | R | R | R | R | S | S | R | S | S | R | I | S | R | ESBL + SXTR + FTR + FOSR
| NA |
TZ 250
E. coli
| 128 | R | R | R | R | R | R | R | R | S | R | R | R | R | R | R | R | R | R | MBL (XDR) + Cross resistance to all fluoroquinolones | NA |